Can this shot help you lose weight and lower cholesterol?
262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new weekly shot called pemvidutide in people with extra weight to see if it helps them lose weight and feel healthier.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 569 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a new weekly shot called pemvidutide in people with extra weight to see if it helps them lose weight and feel healthier.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 569 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Related Content
Claims (5)
In adults with overweight or obesity, a weekly injection of pemvidutide at 2.4 mg for 48 weeks resulted in nearly half of the participants achieving a body mass index below 30 kg/m², which is the clinical threshold for no longer being classified as obese.
In adults with overweight or obesity, taking weekly pemvidutide at doses up to 2.4 mg for 48 weeks is linked to only small increases in heart rate and no meaningful changes in blood sugar or HbA1c levels.
In adults with overweight or obesity, taking 2.4 mg of pemvidutide once a week leads to more weight loss than taking 1.2 mg or 1.8 mg weekly, suggesting that higher doses produce greater effects.
In adults with overweight or obesity and at least one related health condition, a weekly injection of pemvidutide for 48 weeks resulted in an average weight loss of 15.6%, compared to 2.2% with a placebo. Over half of those receiving the treatment lost at least 15% of their body weight, and nearly half no longer met the clinical definition of obesity.
In adults with excess weight and high blood fats, a weekly injection of pemvidutide for 48 weeks lowers triglycerides, total cholesterol, and LDL cholesterol by specific percentages, even if body weight does not change.